Cullinan Therapeutics, Inc. (CGEM)

Over the past six months, Cullinan Therapeutics' stock experienced analyst rating changes, including upgrades and downgrades from various firms. The company reported its quarterly earnings data on November 6, 2025, beating analysts' consensus estimates for EPS. Insiders sold 33,420 shares of company stock valued at $356,082. Cullinan Therapeutics outlined anticipated business milestones for 2026 and reported preliminary cash and investments. The company discontinued the CLN-619 and CLN-617 programs to reallocate resources. As of February 7, 2026, the stock was trading at $12.23, with a 6-month increase of 67.65% and a 1-year increase of 19.78%.

As a clinical-stage biopharmaceutical company, Cullinan Therapeutics does not generate revenue from commercial product sales, so traditional consumer demand seasonality is not directly applicable. Investor interest, the progress of its clinical pipeline, and potential future partnerships primarily drive demand. The biopharmaceutical market is experiencing significant growth, influenced by increasing approvals for new therapies, improved safety profiles, and the rising prevalence of chronic diseases. Clinical trial readouts and regulatory milestones are critical events influencing its trajectory.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and immuno-oncology therapies. The company identifies high-impact targets to inhibit disease drivers or leverage the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its diversified pipeline includes zipalertinib for NSCLC, CLN-978 for autoimmune diseases, CLN-619 for solid tumors and multiple myeloma, CLN-049 for AML or MDS, CLN-617 for solid tumors, and CLN-418 for multiple solid tumors. The company also has collaboration agreements with Adimab, LLC and Taiho Pharmaceutical Co., Ltd.

Cullinan Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States, with its development and focus primarily within the United States.

Cullinan Therapeutics holds a "Moderate Buy" consensus rating from analysts, driven by its promising pipeline. The decision to discontinue the CLN-619 and CLN-617 programs demonstrates financial discipline. The company's participation in investor conferences contributes to its visibility.

Cullinan Therapeutics, Inc. has a significant institutional ownership base, with 258 institutional owners and shareholders holding 66,377,493 shares. Major institutional shareholders include MPM Oncology Impact Management LP, Lynx1 Capital Management LP, Bvf Inc/il, BlackRock, Inc., Vanguard Group Inc, Deerfield Management Company, L.p. (series C), Blue Owl Capital Holdings LP, Kynam Capital Management, LP, Citadel Advisors Llc, and Orbimed Advisors Llc. Institutional ownership stands at approximately 86.31% of the stock, while insiders own 7.16%.